CTLA4 and non-small cell lung carcinoma: Conversely, when PD‐1/PD‐L1 inhibitors are used in combination with other types of ICIs for NSCLC treatment, there is an increased irAEs impacting the skin, digestive system and musculoskeletal system, compared to when PD‐1/PD‐L1 and CTLA‐4 inhibitors are used together4, 7, 31, 48, 52 (Table 1).